Antibody Discovery Market (By Methods: Phage Display, Hybridoma, Others; By Antibody Type: Humanized Antibody, Human Antibody, Chimeric Antibody, Murine Antibody; By End Users: Pharmaceutical and Biotechnology industry, Research laboratory, Academic laboratory) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antibody Discovery Market 

5.1. COVID-19 Landscape: Antibody Discovery Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antibody Discovery Market, By Methods

8.1. Antibody Discovery Market, by Methods, 2023-2032

8.1.1 Phage Display

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Hybridoma

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Antibody Discovery Market, By Antibody Type

9.1. Antibody Discovery Market, by Antibody Type, 2023-2032

9.1.1. Humanized Antibody

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Human Antibody

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Chimeric Antibody

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Murine Antibody

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Antibody Discovery Market, By End Users 

10.1. Antibody Discovery Market, by End Users, 2023-2032

10.1.1. Pharmaceutical and Biotechnology industry

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Research laboratory

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Academic laboratory

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Antibody Discovery Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Methods (2020-2032)

11.1.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.1.3. Market Revenue and Forecast, by End Users (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Methods (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.1.4.3. Market Revenue and Forecast, by End Users (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Methods (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.1.5.3. Market Revenue and Forecast, by End Users (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Methods (2020-2032)

11.2.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.2.3. Market Revenue and Forecast, by End Users (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Methods (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.2.4.3. Market Revenue and Forecast, by End Users (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Methods (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.2.5.3. Market Revenue and Forecast, by End Users (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Methods (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.2.6.3. Market Revenue and Forecast, by End Users (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Methods (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.2.7.3. Market Revenue and Forecast, by End Users (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Methods (2020-2032)

11.3.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.3.3. Market Revenue and Forecast, by End Users (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Methods (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.3.4.3. Market Revenue and Forecast, by End Users (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Methods (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.3.5.3. Market Revenue and Forecast, by End Users (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Methods (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.3.6.3. Market Revenue and Forecast, by End Users (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Methods (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.3.7.3. Market Revenue and Forecast, by End Users (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Methods (2020-2032)

11.4.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.4.3. Market Revenue and Forecast, by End Users (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Methods (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.4.4.3. Market Revenue and Forecast, by End Users (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Methods (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.4.5.3. Market Revenue and Forecast, by End Users (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Methods (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.4.6.3. Market Revenue and Forecast, by End Users (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Methods (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.4.7.3. Market Revenue and Forecast, by End Users (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Methods (2020-2032)

11.5.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.5.3. Market Revenue and Forecast, by End Users (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Methods (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.5.4.3. Market Revenue and Forecast, by End Users (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Methods (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Antibody Type (2020-2032)

11.5.5.3. Market Revenue and Forecast, by End Users (2020-2032)

Chapter 12. Company Profiles

12.1. Danaher Corporation

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Eurofins Scientific

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Evotec

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Twist Bioscience

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Charles River Laboratories

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Genscript Technology Corporation

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Biocytogen

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Sartorius AG

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Fairjourney Biologics S.A

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Creative Biolabs

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample